DOTS in Haiti.
Ollé-Goig, J E.
Int J Tuberc Lung Dis
; 4(3): 282-3, 2000 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-10751080
New structural classes of antituberculosis agents.
New insights into TB physiology suggest untapped therapeutic opportunities.
The Role of Efflux Pumps in Tuberculosis Treatment and Their Promise as a Target in Drug Development: Unraveling the Black Box.
Nonclinical models for antituberculosis drug development: a landscape analysis.
Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing.
Bacterial Factors That Predict Relapse after Tuberculosis Therapy.
Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach.
Improved power for TB Phase IIa trials using a model-based pharmacokinetic-pharmacodynamic approach compared with commonly used analysis methods.
A high content microscopy assay to determine drug activity against intracellular Mycobacterium tuberculosis.
Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia.